drugset / Trial / NCT05148299
A Study of Pegcetacoplan for Patients With Transplant-associated Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplantation
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the study was to assess pharmacokinetics (PK), pharmacodynamics (PD), efficacy, and safety of pegcetacoplan in patients with TA-TMA after HSCT.
Timeline
- Start
- 2022-02-01
- Primary completion
- 2024-12-08
- Completion
- 2024-12-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pegcetacoplan | Peptide | 1080 mg | Other |